Celltrion Touts HER2 Bispecific Cancer Data, Eyes FDA Fast-Track in 2026

2026年6月12日

執筆 MinJeKim0 回閲覧

この記事の日本語訳は準備中です。以下は英語の原文です。

Celltrion Touts HER2 Bispecific Cancer Data, Eyes FDA Fast-Track in 2026

Celltrion (068270.KS), one of South Korea's two largest biopharmaceutical companies by revenue alongside Samsung Biologics and best known for biosimilars such as Remsima, on June 11 presented interim preclinical results for CT-P72/ABP-102, a HER2-targeting T-cell engager it is developing as a proprietary cancer drug rather than a biosimilar copy. The disclosure, made at the World Bispecific and T-Cell Engager Summit South Korea at COEX Magok Le West in Seoul's Gangseo-gu district, was reported by Electronic Times (etnews) and Maeil Business Newspaper (MK), Korea's leading economic daily.

The immediate question for an investor is how much this advances Celltrion's pivot from biosimilars into novel oncology, and the honest answer is that the data remains early. CT-P72/ABP-102 is preclinical-stage; the candidate received U.S. FDA clearance of its Investigational New Drug (IND) application on January 6, 2026, and is now in patient-screening for a Phase 1 trial, according to a joint statement from Celltrion and its U.S. development partner Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage antibody biotech that became publicly traded in November 2024 via a SPAC merger with Atlantic Coastal Acquisition Corp. II. Celltrion says it intends to apply for FDA fast-track designation within 2026, as reported by etnews and MK. No human efficacy data exists yet.

What the molecule is. CT-P72/ABP-102 is a multispecific HER2 x CD3 T-cell engager (TCE) — a type of antibody designed to grab a cancer cell on one arm and a cytotoxic T cell on the other, forcing the immune system to attack the tumor. Per the Abpro–Celltrion press release, it is engineered to bind HER2-overexpressing tumor cells while limiting activity in normal HER2-low tissue, the central safety problem that has historically held TCEs back in solid tumors.

The preclinical numbers. In the data presented, the molecule showed strong killing of HER2-high tumor cells in vitro while killing capacity against HER2-low cells "significantly decreased," indicating selective targeting, according to etnews. In primate pharmacokinetic and toxicity studies, Celltrion reported good tolerability up to a high dose of 80 mg/kg, and said the candidate exceeded the efficacy of existing drugs in treatment-resistant gastric cancer xenograft models (etnews). Celltrion flagged potential indication expansion across HER2-expressing solid tumors including gastric, bladder, biliary tract (cholangiocarcinoma) and breast cancer (etnews, MK).

Sizing it against the company. Celltrion reported 2025 revenue of about ₩4.16 trillion (USD3.04 billion) and carries a market capitalization of about ₩38 trillion (USD27.8 billion), per stockanalysis.com. Against that scale, a single preclinical asset is not yet financially material; its significance is strategic — evidence of whether a biosimilar manufacturer can build a credible first-in-class novel pipeline.

Why the bar is high. T-cell engagers transformed blood-cancer treatment after the FDA approved Amgen's blinatumomab (Blincyto), the first BiTE therapy, on December 3, 2014. Translating that mechanism to solid tumors proved far harder; the FDA approved Amgen's tarlatamab (Imdelltra) on May 16, 2024 as the first T-cell engager for a major solid tumor, extensive-stage small cell lung cancer (Amgen/PRNewswire). HER2 is a heavily validated cancer target — the basis for trastuzumab and Enhertu — but attacking it with a T-cell engager raises the same on-target toxicity risk Celltrion claims its design mitigates. That claim is, for now, supported only by animal and cell data.

What to watch. The first hard read comes from the Phase 1 study Celltrion is leading; the Abpro–Celltrion statement targeted a global Phase 1 start in the first half of 2026, with the program currently in patient screening. A subsequent FDA fast-track decision — which Celltrion says it will seek within the year — and the first human safety and dose-finding data will determine whether the preclinical selectivity story holds in patients. Until then, conference data and regulatory paperwork, not clinical proof, are what is on the table.

This article is for informational purposes only and does not constitute investment advice. Figures are sourced from company statements, regulatory filings and cited news reports; currency conversions use an approximate rate of 1 USD = 1,370 KRW.